Clarus Therapeutics (CRXT) stock
CRXT · Clarus Therapeutics Holdings Inc. · NASDAQ
What is the latest news on CRXT stock?
SECago
SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.
15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
All CRXT newsWhen does Clarus Therapeutics report earnings?
Clarus Therapeutics last reported on May 16, 2022, the date it announced on May 12, 2022. Before that it reported on Mar 30, 2022 and Nov 18, 2021.
CRXT earnings historyLatest news
25 items- SECSEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form POS AM filed by Clarus Therapeutics Holdings Inc.POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form POS AM filed by Clarus Therapeutics Holdings Inc.POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form POS AM filed by Clarus Therapeutics Holdings Inc.POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form POS AM filed by Clarus Therapeutics Holdings Inc.POS AM - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- 13D/GSEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- PRClarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful BidderCourt-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- SECSEC Form 25-NSE filed by Clarus Therapeutics Holdings Inc.25-NSE - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)
- SECClarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Other Events, Financial Statements and Exhibits8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)
- PRClarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy CodeNORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos
- NEWSWhy Nikola Dropped Over 9%; Here Are 66 Biggest Movers From YesterdayGainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares surged 103.9% to settle at $5.30 on Tuesday. Shares are in low-float territory; the issue has about 15 million shares in its float. NewAge, Inc. (NASDAQ:NBEV) shares jumped 74.2% to close at $0.3632 on Tuesday. IN8bio, Inc. (NASDAQ:INAB) surged 39.4% to settle at $2.76 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. TMC the metals company Inc. (NASDAQ:TMC) jumped 33.3% to close at $1.12. The company recently posted a quarterly loss of $0.05 per share. TDH Holdings, Inc. (NASDAQ:P
- NEWSWhy IN8bio Is Trading Higher By 46%, Here Are 54 Stocks Moving In Tuesday's Mid-Day SessionGainers NewAge, Inc. (NASDAQ:NBEV) rose 54.4% to $0.3220. IN8bio, Inc. (NASDAQ:INAB) jumped 46% to $2.89 after a Form 4 Filing showed Cavu Advisors purchased 51,214 shares at an average price of $2.02. HC Wainwright & Co. initiated coverage on IN8bio with a Buy rating and announced a price target of $14. Mobile Global Esports Inc. (NASDAQ:MGAM) shares jumped 45% to $3.7705. Shares are in low-float territory; the issue has about 15 million shares in its float. Forge Global Holdings, Inc. (NYSE:FRGE) gained 26.7% to $4.37. Virax Biolabs Group Limited (NASDAQ:VRAX) gained 20% to $3.94. American Outdoor Brands, Inc. (NASDAQ:AOUT) surged 18% to $9.17 after B. Riley upgraded the stock from
- NEWSStocks That Hit 52-Week Lows On TuesdayOn Tuesday, 250 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Toyota Motor (NYSE:TM) was the biggest company on a market cap basis to set a new 52-week low. SciSparc (NASDAQ:SPRC) was the smallest firm by market cap to set a new 52-week low. Rubicon Technology (NASDAQ:RBCN)'s stock traded down the lowest, falling 74.66% to reach a new 52-week low. Grupo Aval Acciones (NYSE:AVAL)'s stock made the biggest reversal, trading up 0.0% shortly after dropping to a new 52-week low. On Tuesday, the following stocks set new 52-week lows: Toyota Motor (NYSE:TM) stock drifted down 0.45% on Tuesday morning to hit a new 52-week low of $150.59. Comcast (NASDA
- NEWSWhy Baudax Bio Is Trading Lower By 34%; Here Are 26 Stocks Moving PremarketGainers Mobile Global Esports Inc. (NASDAQ:MGAM) shares rose 28.1% to $3.33 in pre-market trading after gaining over 5% on Monday. The company recently reported an exclusive compression technology partnership for upcoming Indian esports social-gaming platform. American Virtual Cloud Technologies, Inc. (NASDAQ:AVCT) shares rose 18.3% to $0.4435 in pre-market trading after jumping 156% on Monday. American Virtual Cloud Technologies recently announced changes to its board of directors and management team, along with the launch of a review to explore the sale of the entire business or selected assets. Sharps Technology, Inc. (NASDAQ:STSS) rose 13.7% to $1.58 in pre-market trading. NewAge,
- NEWSHere's Why Clarus Therapeutics Shares Got ObliteratedClarus Therapeutics Holdings Inc (NASDAQ:CRXT) shares traded lower by 32.24% to $0.14 during Monday's trading session after the company announced it has received a non-compliance letter from Nasdaq. The shares will be suspended on August 31st and will begin trading on the OTC Pink Market. What Else? Clarus Therapeutics says, as previously disclosed on February 18th, 2022, the company received two written notifications from the Listing Qualifications Department of Nasdaq. Clarus Therapeutics says the first notification indicated that as of February 18th, Clarus did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in N
Clarus Therapeutics Holdings Inc. (CRXT) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for CRXT in the last 30 days. The most recent was published Mar 1, 2023.
CRXT FAQ
7 questionsWhat does Clarus Therapeutics Holdings Inc. do?
Clarus Therapeutics Holdings, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen-dependent inflammatory breast disease and certain forms of breast cancer. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.Where does CRXT stock trade?
Clarus Therapeutics Holdings Inc. (CRXT) is listed on NASDAQ.What sector and industry is CRXT in?
Clarus Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Clarus Therapeutics Holdings Inc. go public?
Clarus Therapeutics Holdings Inc. (CRXT) completed its IPO in 2021.What are analysts saying about CRXT?
Clarus Therapeutics Holdings Inc. has had 3 recent analyst actions on file. The most recent action was from Truist Securities: Buy with a $10.00 price target on 2021-10-13. Recent price targets range from $10.00 to $13.00.What companies are similar to CRXT?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), ABT (Abbott Laboratories), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S). Compare CRXT side-by-side with any of them on Quantisnow.How can I track CRXT on Quantisnow?
Quantisnow aggregates Clarus Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRXT to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change